C

ClinOhio Research Services, LLC | Columbus, OH

Research site
(Unclaimed)
Location
150 Taylor Station Road, Suite 100, Columbus, Ohio, United States of America

Site insights

Top conditions

Top treatments

Upadacitinib
Risankizumab
TAK-279
Rocatinlimab

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

4 of 6 total trials

A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period

The main aim of this study is to show how well TAK-279 reduces the skin plaques compared to placebo, in participants with moderate-to-severe plaque p...

Enrolling
Plaque Psoriasis
Drug: Placebo
Drug: TAK-279
Status recently updated

The purpose of this study is to evaluate the efficacy and safety of rocatinlimab in monotherapy treatment.

Enrolling
Active, not recruiting
Atopic Dermatitis
Drug: Rocatinlimab
Drug: Placebo

Vitiligo is a common chronic autoimmune disease that causes the body's immune system to attack its own pigment producing skin cells. This study is to...

Invitation-only
Vitiligo
Drug: Placebo
Drug: Upadacitinib
Locations recently updated

Hidradenitis suppurativa (HS) is an inflammatory skin disease that causes painful lesions in the axilla (underarm), inguinal (groin) and anogenital (...

Enrolling
Hidradenitis Suppurativa
Drug: Upadacitinib
Drug: Placebo

Trial sponsors

AbbVie logo
Amgen logo
G
Takeda logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems